Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer

Hepato-Gastroenterology

Volumn 45, Issue 24, 1998, Pages 2117-2122

  Nita, Marcelo Eidi ^a   Tominaga, Osamu ^a,c   Nagawa, Hirokazu ^a   Tsuruo, Takashi ^b   Muto, Tetsuichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

5 fluorouracil; Chemosensitivity; Colorectal cancer; Dihydropyrimidine dehydrogenase; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ARTICLE; CELL GROWTH; COLORECTAL CANCER; DRUG RESISTANCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; WESTERN BLOTTING;

EID: 0032438744     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Diasio RB, Lu Z: Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 1994; 12:2239-2242.
2. Danenberg PV: Thymidylate synthase: A target enzyme in cancer chemotherapy. Biochem Biophys Acta 1977; 473:73-92.
3. Kaneda S, Nalbantoglu J, Takeishi K, et al: Structural and functional analysis of the human thymidylate synthase gene. J Biol Chem 1990; 265:20277-20284.
4. Harris BE, Song R, Soong SJ, Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50:197-201.
5. Houghton JA, Maroda SJ, Phillips JO, Houghton PJ: Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinoma in mice. Cancer Res 1981; 41:144-149.
6. Santi DV, McHenry CS, Sommer H: Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974; 13:471-481.
7. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH: In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982; 42:450-456.
8. Chu E, Drake JC, Koeller DM, et al: Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 1991; 39:136-143.
9. Chu E, Grem JL, Johnston PG, Allegra CJ: New concepts for the development and use of antifolates. Stem Cells 1996; 14:41-46.
10. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM: Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994; 12:2035-2042.
11. Inaba M, Mitsuhashi J, Sawada H, et al: Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res 1996; 87:212-220.
12. Beck A, Etienne MC, Cheradame S, et al: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 10:1517-1522.
13. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase: Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81:47-51.
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265-275.
15. Wilmink ABM: Overview of the epidemiology of colorectal cancer. Dis Colon Rectum 1997; 40:483-493.
16. National Institutes of Health Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. J Am Med Assoc 1990; 264:1444-1450.
17. Cao S, Baccanari DP, Joyner SS, Davis ST, Rustum YM, Spector T: 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. Cancer Res 1995; 55:6227-6230.
18. Baccanari DP, Davis ST, Knick VC, Spector T: 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 1993; 90:11064-11068.
19. Harris BE, Carpenter JT, Diasio RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 1991; 68:499-501.
20. Stephan F, Etienne MC, Wallays C, Milano G, Clergue F: Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med 1995; 99:685-688.
21. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12:2640-2647.
22. Lenz HJ, Leichman CG, Danenberg KD, et al: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 1995; 14:176-182.
23. Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM: Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986; 46:20-28.
24. Aschele C, Sobrero A, Faderan MA, Bertino JR: Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52:1855-1864.
25. Johnston PG, Lenz HJ, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55:1407-1412.
26. Leichman L, Lenz HJ, Leichman CG, et al: Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 1995; 31:1306-1310.
27. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokin 1989; 16:215-237.
28. Parker WB, Cheng YC: Metabolism and mechanism of action of 5-fluorouracil. Pharm Ther 1990; 48:381-395.
29. Wang FS, Aschele C, Sobrero A, Chang YM, Bertino JR: Decreased folylpolyglutamate synthetase expression: A novel mechanism of fluorouracil resistance. Cancer Res 1993; 53:3677-3680.